| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
7,8-Dihydro-L-biopterin targets GTP cyclohydrolase I, the rate-limiting enzyme in BH4 biosynthesis, acting as a noncompetitive inhibitor with a Ki of 14.4 µM. It also inhibits dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. As a precursor of BH4 synthesis, the compound is involved in the regulation of BH4 levels, which are critical for the function of nitric oxide synthase (NOS), aromatic amino acid hydroxylases, and alkylglycerol monooxygenase. Its role in pterin metabolism makes it a valuable tool for studying BH4-related pathways and their implications in various diseases.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 7,8-Dihydro-L-biopterin is a noncompetitive inhibitor of GTP cyclohydrolase I with a Ki of 14.4 µM. It also inhibits dihydroneopterin aldolase (DHNA). The compound is the oxidation product of tetrahydrobiopterin and is involved in pterin metabolism. Its ability to inhibit key enzymes in BH4 biosynthesis makes it a valuable tool for studying BH4-related pathways. However, detailed in vitro potency data for other targets are not extensively documented in the available literature.
|
| ln Vivo |
In vivo, 7,8-Dihydro-L-biopterin is involved in the regulation of BH4 levels, which are critical for the function of nitric oxide synthase (NOS), aromatic amino acid hydroxylases, and alkylglycerol monooxygenase. Its role as a precursor of BH4 synthesis makes it important for maintaining proper BH4 levels in various tissues. The compound's ability to inhibit GTP cyclohydrolase I suggests that it may play a role in the feedback regulation of BH4 biosynthesis. However, comprehensive in vivo studies on its pharmacokinetics and pharmacodynamics are limited.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for 7,8-Dihydro-L-biopterin typically involve measuring the inhibition of GTP cyclohydrolase I activity using purified enzyme and a substrate such as GTP. The compound is incubated with the enzyme and substrate, and the production of dihydroneopterin triphosphate is measured by HPLC or fluorescence-based methods. Ki values are calculated from steady-state kinetic analysis. The inhibition of dihydroneopterin aldolase (DHNA) can be measured using similar assays with the appropriate substrate. These assays provide quantitative data on the compound's direct interactions with its molecular targets.
|
| Cell Assay |
In vitro cell-based assays for 7,8-Dihydro-L-biopterin use various cell lines to study its effects on BH4 biosynthesis and metabolism. Cells are treated with varying concentrations of the compound, and parameters such as BH4 levels, GTP cyclohydrolase I activity, and nitric oxide production are assessed. The compound's effects on cell viability and proliferation can also be assessed using MTT or similar assays. These studies help to characterize the compound's cellular mechanism of action and its role in pterin metabolism.
|
| Animal Protocol |
In vivo animal studies for 7,8-Dihydro-L-biopterin would likely employ models of BH4 deficiency or diseases associated with BH4 dysregulation, such as phenylketonuria, Parkinson's disease, or hypertension. The compound is administered orally or intraperitoneally, and parameters such as BH4 levels in tissues, nitric oxide production, and disease-specific markers are assessed. Pharmacokinetic studies in these models provide information about the compound's absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
7,8-Dihydro-L-biopterin has a molecular weight of 239.23 g/mol and a molecular formula of C₉H₁₃N₅O₃. It appears as a yellow powder. The compound is also known as BH2, Dihydrobiopterin, and 2-Amino-6-(1,2-dihydroxypropyl)-7,8-dihydro-3H-pteridin-4-one. It should be stored under appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion have not been extensively characterized. As a small molecule pteridine, 7,8-dihydro-L-biopterin is expected to have moderate water solubility and may cross biological membranes.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 7,8-Dihydro-L-biopterin has not been comprehensively evaluated in published studies. As an endogenous metabolite, it is generally considered to have low toxicity at physiological concentrations. The compound's ability to inhibit GTP cyclohydrolase I suggests that it may have significant biological effects at high concentrations. The compound is classified as a research reagent and is not intended for human therapeutic use without further safety evaluation. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
L-Erythro-7,8-dihydrobiopterin is a 7,8-dihydrobiopterin in which the 1,2-dihydroxypropyl group has a (1R,2S) configuration; it is the naturally occurring form. It is the enantiomer of D-Erythro-7,8-dihydrobiopterin. 7,8-Dihydrobiopterin is an inhibitor of dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
7,8-Dihydro-L-biopterin is a pteridine compound and the oxidation product of tetrahydrobiopterin (BH4). It is also known as BH2 and Dihydrobiopterin. The compound is a precursor of BH4 synthesis and a noncompetitive inhibitor of GTP cyclohydrolase I with a Ki of 14.4 µM. It is also an inhibitor of dihydroneopterin aldolase (DHNA). 7,8-Dihydro-L-biopterin appears as a yellow powder. It is an endogenous metabolite involved in pterin metabolism and is used as a research tool for studying BH4 biosynthesis. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C9H13N5O3
|
|---|---|
| Molecular Weight |
239.23122
|
| Exact Mass |
239.101
|
| CAS # |
6779-87-9
|
| PubChem CID |
135398687
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
470.8±55.0 °C at 760 mmHg
|
| Melting Point |
>300℃ dec.
|
| Flash Point |
238.5±31.5 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.822
|
| LogP |
-3.39
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H]([C@@H](C1=NC2=C(NC1)N=C(NC2=O)N)O)O
|
| InChi Key |
FEMXZDUTFRTWPE-DZSWIPIPSA-N
|
| InChi Code |
InChI=1S/C9H13N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,6,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,6-/m0/s1
|
| Chemical Name |
2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydro-3H-pteridin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~627.01 mM)
H2O : ~6 mg/mL (~25.08 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 12.5 mg/mL (52.25 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1801 mL | 20.9004 mL | 41.8008 mL | |
| 5 mM | 0.8360 mL | 4.1801 mL | 8.3602 mL | |
| 10 mM | 0.4180 mL | 2.0900 mL | 4.1801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
